Impact of the 2013 ASCO/CAP HER2 revised guidelines on HER2 results in breast core biopsies with invasive breast carcinoma: a retrospective study

被引：9
|
作者：
Overcast, Wynton B. [1 ]
Zhang, Jianying [2 ]
Zynger, Debra L. [3 ]
Tozbikian, Gary H. [3 ]
机构：
[1] Ohio State Univ, Coll Med, 410 W 10th Ave,E410 Doan Hall, Columbus, OH 43210 USA
[2] Ohio State Univ, Ctr Biostat, 320 Lincoln Tower,1800 Cannon Dr, Columbus, OH 43210 USA
[3] Ohio State Univ, Dept Pathol, Wexner Med Ctr, 410 W 10th Ave,E410 Doan Hall, Columbus, OH 43210 USA
来源：
VIRCHOWS ARCHIV | 2016年 / 469卷 / 02期
关键词：
ASCO/CAP guidelines; Breast cancer; Equivocal category; HER2 immunohistochemistry (IHC); HER2 fluorescence in situ hybridization (FISH); IN-SITU HYBRIDIZATION; POLYMERASE CHAIN-REACTION; CLINICAL ONCOLOGY/COLLEGE; AMERICAN SOCIETY; COPY NUMBER; CANCER; RECEPTOR; IMMUNOHISTOCHEMISTRY; TRASTUZUMAB; FISH;
D O I：
10.1007/s00428-016-1951-8
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
[No abstract available]
引用
收藏
页码：203 / 212
页数：10
相关论文
共 50 条
  • [21] HER2 Gene Protein Assay Is Useful to Determine HER2 Status and Evaluate HER2 Heterogeneity in HER2 Equivocal Breast Cancer
    Hou, Yanjun
    Nitta, Hiroaki
    Li, Zaibo
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2017, 147 (01) : 89 - 95
  • [22] Prediction of HER2 gene status in Her2 2+invasive breast cancer: a study of 108 cases comparing ASCO/CAP and FDA recommendations
    Chibon, Frederic
    de Mascarel, Isabelle
    Sierankowski, Ghislaine
    Brouste, Veronique
    Bonnefoi, Herve
    Debled, Marc
    Mauriac, Louis
    MacGrogan, Gaetan
    MODERN PATHOLOGY, 2009, 22 (03) : 403 - 409
  • [23] Histologic analysis according to HER2 gene status in HER2 2 + invasive breast cancer: a study of 280 cases comparing ASCO/CAP 2013 and 2018 guideline recommendations
    Hye Won Hwang
    Soon Auck Hong
    Seok Jin Nam
    Seok Won Kim
    Jeong Eon Lee
    Jong-Han Yu
    Se Kyung Lee
    Soo Youn Cho
    Eun Yoon Cho
    Virchows Archiv, 2022, 480 : 749 - 758
  • [24] Impact of 2013 ASCO/CAP HER2 reporting guidelines in breast cancer: An assessment study from Indian oncology centre that primarily performs HER2 IHC testing with special emphasis on IHC equivocal category
    Pasricha, Sunil
    Gupta, Gurudutt
    Garg, Ritu
    Sharma, Anila
    Gandhi, Jatin S.
    Durga, Garima
    Kamboj, Meenakshi
    Grover, Shrruti
    Mehta, Anurag
    BREAST JOURNAL, 2018, 24 (04) : 468 - 472
  • [25] Analysis of molecular subtypes for the increased HER2 equivocal cases caused by application of the updated 2013 ASCO/CAP HER2 testing guidelines in breast cancer
    Lei Guo
    Pei Yuan
    Jing Zhang
    Yun Ling
    Wenbin Li
    Bohui Zhao
    Jianming Ying
    Lixue Xuan
    Breast Cancer Research and Treatment, 2017, 166 : 77 - 84
  • [26] ASCO/CAP 2018 breast cancer HER2 testing guidelines: summary of pertinent recommendations for practice in Australia
    Farshid, Gelareh
    Bilous, Michael
    Morey, Adrienne
    Fox, Stephen
    Lakhani, Sunil
    Loi, Sherene
    Bell, Richard
    Spillane, Andrew
    PATHOLOGY, 2019, 51 (04) : 345 - 348
  • [27] HER2 equivocal breast cancer that is positive by alternative probe HER2 FISH are classified as HER2 negative by Oncotype DX
    Tozbikian, Gary H.
    Zynger, Debra L.
    BREAST JOURNAL, 2018, 24 (04) : 535 - 540
  • [28] Impact of the 2013 ASCO/CAP HER2 Guideline Updates at an Academic Medical Center That Performs Primary HER2 FISH Testing Increase in Equivocal Results and Utility of Reflex Immunohistochemistry
    Muller, Kristen E.
    Marotti, Jonathan D.
    Memoli, Vincent A.
    Wells, Wendy A.
    Tafe, Laura J.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2015, 144 (02) : 247 - 252
  • [29] Application of the 2013 ASCO/CAP guideline and the SISH technique for HER2 testing of breast cancer selects more patients for anti-HER2 treatment
    Polonia, Antonio
    Leitao, Dina
    Schmitt, Fernando
    VIRCHOWS ARCHIV, 2016, 468 (04) : 417 - 423
  • [30] HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
    Morsberger, Laura
    Pallavajjala, Aparna
    Long, Patty
    Hardy, Melanie
    Park, Rebecca
    Parish, Rebecca
    Nozari, Azin
    Zou, Ying S.
    CANCER CELL INTERNATIONAL, 2022, 22 (01)
12345